Taking people in FranceNo phase

Quick Action-Speed Tests in Stroke and Memory-Related Brain Diseases

Studies whether quick tests of action speed can help assess stroke and memory-related brain disease.

Key facts

Who runs it: Centre Hospitalier Universitaire, Amiens
Where: Amiens, FranceSee the site
Trial code: NCT05785156
Registry title: Diagnostic and Prognostic Value of New Quick Tests of Action Slowing in Stroke and in Cognitive Neurodegenerative Disease
Status: Recruiting
People taking part: 129 people, planned
Started: 16 Jul 2021
Expected to end: 16 Jul 2027
Type of study: Observational, 2 groups
Treatments tested: quick tests
Record updated: 13 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40 to 85 with acute stroke or with a memory and thinking disease such as Alzheimer's, Lewy body disease, frontotemporal degeneration, corticobasal degeneration or progressive supranuclear palsy.

Age: 40 to 85 years
Sex: Men and women can join.
Disease stage: Acute stroke, or a neurodegenerative disease seen at a memory clinic: mild (MMSE above 19) or major severity disorder related to Alzheimer's disease, and Lewy body disease, frontotemporal lobar degeneration, corticobasal degeneration or progressive supranuclear palsy by the named criteria.
Earlier treatment: People on gold salts, D-Penicillamine or another treatment with an effect on thinking cannot join.

Main reasons for not taking part

Dementia diagnosed before
Other current or past brain disease, such as Parkinson disease, multiple sclerosis, brain tumour or severe head trauma
Cannot have an MRI scan
Life expectancy under 1 year
Illness that affects thinking, such as kidney, liver, heart or breathing failure, or heavy alcohol or drug use

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

Patients between 40 and 85 years old,
French native language,
Social Security affiliation
University Memory Clinic for: Mild severity disorder (MMSE> 19) or major severity disorder related to AD : Albert 2011 criteria ; McKhann 2011
to MCL according to McKeith criteria
to FTLD according to Rascovsky 2011 criteria
BBD according to Armstrong's criteria
related to PSP according to Höglinger criteria

Who cannot take part

Previously diagnosed dementia
epilepsy prior to stroke still requiring previous treatment
brain tumor or brain radiation therapy
treatment with gold salts, D Penicillamine or other treatment with cognitive effect
Other current or past brain condition
Parkinson disease, multiple sclerosis
Active or past psychiatric disorders requiring a stay> 2 days in a specialized environment
Alcohol (> 3 glasses / day) or history of alcohol withdrawal syndrome
opiate or cocaine addiction or opiate withdrawal syndrome
respiratory failure requiring oxygen therapy
heart failure (orthopnea> 2 pillows)
cancer with paraneoplastic syndrome
renal failure (dialysis or creatinine clearance <30)
hepatic failure (spontaneous INR> 1.5 or PT <60%)
Mental retardation or guardianship
severe head trauma
Current or past schizophrenia or psychosis
Contra indication to MRI
Comorbidity with life expectancy <1 year
Comorbidity affecting cognition in particular:
persistent vigilance disturbances (NIHSS1a score ≤1)
Patient under guardianship or curators or private under public law
Pregnant and / or lactating wom

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 40 and 85 years old?

Where in France

CHU AmiensAmiens, FranceContact: Martine Roussel, PhDTaking people

About the trial

What the trial wants to find out

A large series of recent studies have documented the frequency of the slowing of the action in brain diseases, especially vascular and neurodegenerative diseases. In stroke, the predictive value of action slowing at the acute phase for predicting post-stroke functional outcome remains poorly investigated. In neurodegenerative diseases, the diagnostic relevance of the slowing at the prodromal stage remains unknown and this diagnostic requires new tests. Finally, in terms of anatomical determinants, few studies have studied the determinants of action slowing. The objectives of this project are to Determine the diagnostic and prognostic value of action slowing assessed with new quick tests in patients with acute stroke (Neurovascular Unit) and cognitive neurodegenerative disorders (Alzheimer Disease (AD), Lewy Body disease (LBD), Fronto Temporal lobar degeneration (FTLD), Cortico Basal Degeneration (CBD) and Progressive Supra Nuclear Palsy (PSNP)) and to define the lesion determinants with VBM and VLSM

The 2 groups in the trial

acute stroke patients
Treatment: quick tests
cognitive neurodegenerative disorders
cognitive neurodegenerative disorders (Alzheimer Disease (AD), Lewy Body disease (LBD), FrontoTemporal lobar degeneration (FTLD), Cortico Basal Degeneration (CBD) and Progressive Supra Nuclear Palsy (PSNP)
Treatment: quick tests